WO2013048158A3 - 유파틸린의 신규 용도 - Google Patents

유파틸린의 신규 용도 Download PDF

Info

Publication number
WO2013048158A3
WO2013048158A3 PCT/KR2012/007841 KR2012007841W WO2013048158A3 WO 2013048158 A3 WO2013048158 A3 WO 2013048158A3 KR 2012007841 W KR2012007841 W KR 2012007841W WO 2013048158 A3 WO2013048158 A3 WO 2013048158A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
eupatilin
obesity
condition selected
present
Prior art date
Application number
PCT/KR2012/007841
Other languages
English (en)
French (fr)
Other versions
WO2013048158A2 (ko
Inventor
최정혜
이경태
김지현
백남인
Original Assignee
경희대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경희대학교 산학협력단 filed Critical 경희대학교 산학협력단
Priority to US14/348,453 priority Critical patent/US9301943B2/en
Priority to CN201280046194.8A priority patent/CN103917232B/zh
Publication of WO2013048158A2 publication Critical patent/WO2013048158A2/ko
Publication of WO2013048158A3 publication Critical patent/WO2013048158A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 유파틸린의 골질환(bone disease), 갱년기 장애(menopausal disorder), 심혈관계질환(cardiovascular disease), 퇴행성뇌질환 (neurodegenerative disease) 또는 비만 (Obesity) 중에서 선택된 하나 이상의 치료, 개선 및/또는 예방을 위한 의약 및/또는 식품 용도를 제공한다. 본 발명에 의해 암과 같은 부작용 가능성이 없거나 적으며 골질환(bone disease), 갱년기 장애(menopausal disorder), 심혈관계질환(cardiovascular disease), 퇴행성뇌질환 (neurodegenerative disease) 또는 비만 (Obesity) 중에서 선택된 하나 이상을 효과적으로 치료, 개선 및/또는 예방할 수 있다는 장점이 있다.
PCT/KR2012/007841 2011-09-29 2012-09-27 유파틸린의 신규 용도 WO2013048158A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/348,453 US9301943B2 (en) 2011-09-29 2012-09-27 Use of eupatilin
CN201280046194.8A CN103917232B (zh) 2011-09-29 2012-09-27 异泽兰黄素的新用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0099349 2011-09-29
KR1020110099349A KR101292741B1 (ko) 2011-09-29 2011-09-29 유파틸린의 신규 용도

Publications (2)

Publication Number Publication Date
WO2013048158A2 WO2013048158A2 (ko) 2013-04-04
WO2013048158A3 true WO2013048158A3 (ko) 2013-05-23

Family

ID=47996635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007841 WO2013048158A2 (ko) 2011-09-29 2012-09-27 유파틸린의 신규 용도

Country Status (4)

Country Link
US (1) US9301943B2 (ko)
KR (1) KR101292741B1 (ko)
CN (1) CN103917232B (ko)
WO (1) WO2013048158A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447681B2 (en) 2011-09-26 2016-09-20 Saudi Arabian Oil Company Apparatus, program product, and methods of evaluating rock properties while drilling using downhole acoustic sensors and a downhole broadband transmitting system
WO2017146309A1 (ko) * 2016-02-22 2017-08-31 (주)오스티오뉴로젠 유파틸린의 상피간엽이행 억제 활성을 이용한 섬유증 예방 및 치료용 약제학적 조성물로서의 새로운 용도
GB201714777D0 (en) * 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN107812001A (zh) * 2017-12-15 2018-03-20 中国药科大学 柳穿鱼黄素用作6‑OHDA神经毒拮抗剂、α‑突触核蛋白抑制剂和防治帕金森用途
KR101871166B1 (ko) * 2018-02-27 2018-07-02 (주)오스티오뉴로젠 신규 화합물 및 이를 유효성분으로 함유하는 섬유증 또는 비알코올성 지방간염의 예방, 개선 또는 치료용 조성물
KR102091464B1 (ko) * 2019-08-30 2020-03-20 (주)오스티오뉴로젠 항염증용 조성물
CN110496120A (zh) * 2019-09-09 2019-11-26 南开大学 表皮生长因子受体拮抗剂及其应用
KR102160424B1 (ko) * 2020-05-14 2020-09-29 경북대학교 산학협력단 유파틸린을 유효성분으로 포함하는 비만 예방, 치료, 또는 개선용 조성물
CN112353792A (zh) * 2020-10-29 2021-02-12 南通大学 异泽兰黄素在制备预防或治疗酒精性肝病药物中的应用
KR102443583B1 (ko) * 2021-04-20 2022-09-15 (주)오스티오뉴로젠 세포 노화 및 세포사멸을 유도하는 항암 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060121998A (ko) * 2005-05-24 2006-11-30 재단법인서울대학교산학협력재단 유파틸린을 포함하는 유방암 억제용 조성물
KR100742737B1 (ko) * 2005-05-24 2007-07-25 재단법인서울대학교산학협력재단 유파틸린을 유효성분으로 함유함을 특징으로 하는 세포 간갭 결합 장애 매개 질환의 예방용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100414453B1 (ko) 1996-07-12 2004-04-03 동아제약 주식회사 염증성장질환치료제용쑥추출물
US5874084A (en) * 1996-07-19 1999-02-23 Yng-Wong; Quing Non Using complex herbal formulations to treat hot flashes
KR100445334B1 (ko) 2001-05-29 2004-08-18 한국생명공학연구원 그늘쑥의 잎으로부터 유파티린과 자세오시딘의 추출방법및 이를 함유하는 조성물
KR100900725B1 (ko) 2008-02-14 2009-06-05 지엘팜텍 주식회사 고함량의 유파틸린을 함유하는 쑥 추출물의 제조방법
KR101080648B1 (ko) * 2009-02-26 2011-11-09 서울대학교산학협력단 쑥속（Ａｒｔｅｍｉｓｉａ　ｓｐｅｃｉｅｓ）식물의 추출물로부터 원심향류분배 크로마토그래피를 이용한 고농도 유파티린(Ｅｕｐａｔｉｌｉｎ) 및 자세오시딘（Ｊａｃｅｏｓｉｄｉｎｅ）을 대량으로 분리 및생산하는 방법
US20120277171A1 (en) 2011-04-28 2012-11-01 Jose Luis Silva Martinot Warmi®, natural alternative for the treatment of menopause

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060121998A (ko) * 2005-05-24 2006-11-30 재단법인서울대학교산학협력재단 유파틸린을 포함하는 유방암 억제용 조성물
KR100742737B1 (ko) * 2005-05-24 2007-07-25 재단법인서울대학교산학협력재단 유파틸린을 유효성분으로 함유함을 특징으로 하는 세포 간갭 결합 장애 매개 질환의 예방용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AN, SO-JIN ET AL.: "Eupatilin attenuates atherosclerosis and improves adipokine profiles in LDL receptor-deficient mice", THE KOREAN SOCIETY OF MEDICAL CROP SCIENCE, May 2008 (2008-05-01), pages 168 - 169 *
CHO, JUNG-HOON ET AL.: "Eupatilin, a dietary flavonoid, induces G2/M cell cycle arrest in human endometrial cancer cells", FOOD AND CHEMICAL TOXICOLOGY, vol. 49, 29 April 2011 (2011-04-29), pages 1737 - 1744, XP028288888 *
RYU, SU-NOH ET AL., KOREAN J. INTL. AGRI., vol. 20, no. 4, 2008, pages 308 - 314 *

Also Published As

Publication number Publication date
KR101292741B1 (ko) 2013-08-02
US20140288168A1 (en) 2014-09-25
WO2013048158A2 (ko) 2013-04-04
US9301943B2 (en) 2016-04-05
KR20130035083A (ko) 2013-04-08
CN103917232A (zh) 2014-07-09
CN103917232B (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
WO2013048158A3 (ko) 유파틸린의 신규 용도
SG10201903119QA (en) Polypeptide vaccine
NZ708727A (en) Conjugate compounds
CR20120202A (es) Métodos y composiciones para tratar cáncer
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
SI2550091T1 (sl) Stroj za obdelavo zmesi hrane
WO2011139489A3 (en) Compounds that modulate intracellular calcium
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2012170931A3 (en) Compounds that modulate intracellular calcium
WO2012027710A3 (en) Compounds that modulate intracellular calcium
MX2010010303A (es) Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
EP3102220C0 (en) SYNERGIC FOOD SUPPLEMENT COMPOSITIONS FOR THE PREVENTION, TREATMENT OR REGULATION OF INFLAMMATORY DISORDERS
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
MX2014005765A (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
WO2013120022A3 (en) Treatment of hypoglycemia
WO2011139765A3 (en) Compounds that modulate intracellular calcium
WO2011034962A3 (en) Compounds that modulate intracellular calcium
WO2012170951A3 (en) Compounds that modulate intracellular calcium
IN2015KN00492A (ko)
EP3603657A4 (en) COMPOSITION CONTAINING AMOMUM VILLOSUM EXTRACT FOR THE PREVENTION, REDUCTION OR TREATMENT OF OBESITY
WO2012017321A3 (en) Treatment for dyslipidemia
EP3189849A4 (en) Novel peptide for inhibiting fat accumulation, and pharmaceutical composition for preventing or treating obesity, comprising same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 14348453

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12837460

Country of ref document: EP

Kind code of ref document: A2